Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Natural Alternatives

This article was originally published in The Tan Sheet

Executive Summary

San Marcos, Calif.-based supplement firm reports sales increase of 36% to $22.7 mil. with earnings up 50% to $852,000 in the first fiscal quarter. CEO Mark Le Doux said sales are in line with fiscal 2005 growth plans, and that Natural Alternatives is "beginning to see brand preference develop" in its contract manufacturing business. In its last earnings call, the firm maintained it will continue investments in facilities and equipment throughout the fiscal year (1"The Tan Sheet" Sept. 29, 2004, In Brief)...

You may also be interested in...



Natural Alternatives

San Marcos, Calif.-based supplement firm's net sales increased 45% to $23.3 mil. in the fiscal fourth quarter (ended June 30). For the year, net sales totalled $78.5 mil., up 40%, and income jumped to $3 mil, up 171%. Year-end results for the fiscal year included a 50% increase in private label contract manufacturing sales. Natural Alternatives "invested heavily" in facilities and equipment in fiscal 2004 and "will continue those investments in fiscal 2005," according to President Randell Weaver...

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097462

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel